Qué cambió
Qué cambióThe European Medicines Agency recommended adding the option of a Bexsero vaccine booster dose for individuals aged 10 years and older. The change applies to patients who completed primary immunization at least two years earlier.

Qué cambióGSK plc ha acordado con Chimagen Biosciences adquirir los derechos mundiales completos de un engager de células T trispecífico. El valor potencial total del acuerdo asciende a hasta 750 millones de dólares. La compañía afirma que se espera que el programa entre en ensayos clínicos en 2027.

Historial de la empresa
Octubre 2026
GSK plc: 12 recorded developments from 7 official sources in 2026-10.
- 2026-09-22: An Independent Non-Executive Director purchased 936 Ordinary Shares of GSK plc at £18.8100 per share. Fuente
- 2026-09-24: Maya Martinez-Davis, President, US, acquired notional ADS within her GSK Executive Supplemental Savings Plan account. Fuente
- 2026-09-24: The transaction involved a price of $50.7200 and a volume of 9.414 American Depositary Shares (ADS). Fuente
- 2026-09-24: The transaction is a single transaction with no aggregated volume or price information applicable. Fuente
- 2026-10-01: The total number of voting rights figure may be used by shareholders as the denominator for calculations to determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparen Fuente
- 2026-10-06: The notification covers the date range from 7 August 2026 to 2 October 2026 for the admission of securities to trading. Fuente
- 2026-10-08: Wendy Becker, an independent Non-Executive Director of GSK plc, has been appointed as a Non-Executive Director of Tesco PLC with effect from 1 November 2026. Fuente
- 2026-10-13: Acquisition of Ordinary Shares under the Company's Share Reward Plan at a price of £17.6539 for a volume of 7 (partnership shares) and £17.6539 for a volume of 7 (matching shares). Fuente
- 2026-10-14: Shobie Ramakrishnan, Chief Digital and Technology Officer, has an interest in American Depositary Shares (‘ADS’) of GSK plc Fuente
- 2026-10-14: David Redfern, President, Corporate Development, has an interest in Ordinary shares of 31 ¼ pence each (Ordinary Shares) of GSK plc Fuente
- 2026-10-14: David Redfern, President, Corporate Development, increased notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan Fuente
- 2026-10-14: Julie Brown acquired Ordinary Shares following the re-investment of dividends paid on 8 October 2026 on Ordinary Shares held in the Company’s Performance Share Plan subject to a 2-year holding period Fuente
Los registros mensuales los redacta la IA a partir de los informes y fuentes oficiales verificados de cada mes (en inglés, tal como se extrajeron), y cada línea enlaza su fuente; las líneas argumentales agrupan hechos relacionados entre análisis mediante embeddings vectoriales (Amazon Titan Text Embeddings V2). Contexto provisional, no es asesoramiento de inversión.
Comparables del sector
Comparación con 36 empresas seguidas en Salud (mediana de ingresos +7,2% a/a), según datos XBRL de la SEC.
| Empresa | Últimos ingresos | Ingresos a/a | Margen operativo |
|---|
| GSK plc GSK | — | — | — |
| Unitedhealth Group Inc UNH | 113 mil M $ | -0,4% | 5,8% |
| Mckesson Corp MCK | 111 mil M $ | +7,6% | 1,4% |
| CVS Health Corp CVS | 108 mil M $ | +5,4% | 3,3% |
| Cigna Group CI | 73,7 mil M $ | +5,6% | 3,3% |
| Cardinal Health Inc CAH | 67,5 mil M $ | +5,5% | 1,1% |
| Elevance Health, Inc. ELV | 51,4 mil M $ | +1,4% | 2,5% |
Último periodo reportado por empresa en SEC CompanyFacts (XBRL). Los calendarios fiscales pueden diferir.
Grandes fondos (13F)
| Fondo | Acciones | Valor | Cambio en acciones | Trimestre |
|---|
| Fidelity (FMR) | 64.920.926 | $3.127.240.971 | -0,1% | T3 2026 |
| Wellington Management | 9.650.852 | $464.881.541 | -15,3% | T3 2026 |
| State Street | 5.940.605 | $288.838.444 | -0,3% | T3 2026 |
| BlackRock | 3.408.608 | $164.192.624 | -5,8% | T3 2026 |
| D. E. Shaw & Co. | 1.954.472 | $94.146.916 | +91,7% | T3 2026 |
| Citadel Advisors | 1.165.967 | $56.164.631 | +669,2% | T3 2026 |
| Bridgewater Associates | 548.661 | $26.429.000 | +8,8% | T3 2026 |
| Renaissance Technologies | 466.340 | $22.463.598 | +49,8% | T3 2026 |
| Norges Bank (Norway's sovereign fund) | 200.000 | $10.484.000 | — | T2 2026 |
| Two Sigma Investments | 186.489 | $8.983.175 | +162,7% | T3 2026 |
| T. Rowe Price | 6.712.097 | $323.323 | -3,1% | T3 2026 |
| Millennium Management | 4067 | $224.458 | — | T1 2026 |
De los informes trimestrales 13F-HR de los grandes fondos que seguimos, tal como se presentaron. Los fondos informan hasta 45 días después del cierre del trimestre, por lo que las posiciones pueden haber cambiado. Cambio: frente al trimestre anterior del mismo fondo. No es una recomendación.